Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Epigral Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Epigral şirketinin toplam hissedar öz sermayesi ₹12.5B ve toplam borcu ₹9.6B olup, bu da borç-öz sermaye oranını 76.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹27.9B ve ₹15.4B dir. Epigral 'in FAVÖK'ü ₹4.4B faiz karşılama oranı 6.3 dur. Şirketin ₹31.8M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

76.9%

Borç/özkaynak oranı

₹9.64b

Borç

Faiz karşılama oranı	6.3x
Nakit	₹31.83m
Eşitlik	₹12.54b
Toplam yükümlülükler	₹15.40b
Toplam varlıklar	₹27.94b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 04

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Nov 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EPIGRAL 'nin kısa vadeli varlıkları ( ₹5.0B ) kısa vadeli yükümlülüklerini ( ₹7.8B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: EPIGRAL 'un kısa vadeli varlıkları ( ₹5.0B ) uzun vadeli yükümlülüklerini ( ₹7.6B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EPIGRAL 'nin net borç/öz sermaye oranı ( 76.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: EPIGRAL 'nin borç/öz sermaye oranı son 5 yılda 82.3% seviyesinden 76.9% seviyesine düştü.

Borç Kapsamı: EPIGRAL 'nin borcu işletme nakit akışı ( 41.2% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: EPIGRAL 'in borcuna ilişkin faiz ödemeleri EBIT ( 6.3 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Epigral Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)

Investor sentiment improves as stock rises 15%

Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)

Epigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024

Investor sentiment improves as stock rises 22%

Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Investor sentiment improves as stock rises 23%

Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)

Now 23% overvalued after recent price rise

Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)

Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023

First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)

Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023

Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

Investor sentiment improves as stock rises 15%

Chairman & MD recently bought ₹4.8m worth of stock

Chairman & MD recently bought ₹2.9m worth of stock

Insider recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)

Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023

Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023

Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)

With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)

Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022

Investor sentiment improved over the past week

Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Investor sentiment improved over the past week

Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022

Investor sentiment improved over the past week

CEO, MD & Director recently bought ₹799k worth of stock

Insider recently bought ₹762k worth of stock

Investor sentiment improved over the past week

Insider recently bought ₹8.3m worth of stock

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Investor sentiment improved over the past week

No independent directors

No independent directors

No independent directors

CEO, MD & Director recently bought ₹5.0m worth of stock

No independent directors

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin